Mainz Biomed (MYNZ) Competitors $1.48 -0.06 (-3.90%) Closing price 04:00 PM EasternExtended Trading$1.49 +0.01 (+0.68%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MYNZ vs. TENX, MAAQ, ANVS, RANI, SCYX, IMA, XCUR, KZR, AKTX, and RNTXShould you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include Tenax Therapeutics (TENX), Mana Capital Acquisition (MAAQ), Annovis Bio (ANVS), Rani Therapeutics (RANI), SCYNEXIS (SCYX), ImageneBio (IMA), Exicure (XCUR), Kezar Life Sciences (KZR), Akari Therapeutics (AKTX), and Rein Therapeutics (RNTX). These companies are all part of the "pharmaceutical products" industry. Mainz Biomed vs. Its Competitors Tenax Therapeutics Mana Capital Acquisition Annovis Bio Rani Therapeutics SCYNEXIS ImageneBio Exicure Kezar Life Sciences Akari Therapeutics Rein Therapeutics Mainz Biomed (NASDAQ:MYNZ) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends. Which has more risk and volatility, MYNZ or TENX? Mainz Biomed has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Do analysts prefer MYNZ or TENX? Mainz Biomed currently has a consensus price target of $14.00, suggesting a potential upside of 845.95%. Tenax Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 157.88%. Given Mainz Biomed's higher possible upside, equities analysts clearly believe Mainz Biomed is more favorable than Tenax Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Tenax Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 Do institutionals and insiders hold more shares of MYNZ or TENX? 1.7% of Tenax Therapeutics shares are owned by institutional investors. 3.7% of Tenax Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger earnings and valuation, MYNZ or TENX? Tenax Therapeutics has lower revenue, but higher earnings than Mainz Biomed. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMainz Biomed$659.94K12.14-$21.65M-$65.60-0.02Tenax TherapeuticsN/AN/A-$17.60M-$0.92-7.59 Is MYNZ or TENX more profitable? Mainz Biomed's return on equity of 0.00% beat Tenax Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mainz BiomedN/A N/A N/A Tenax Therapeutics N/A -31.34%-30.39% Does the media refer more to MYNZ or TENX? In the previous week, Mainz Biomed had 2 more articles in the media than Tenax Therapeutics. MarketBeat recorded 5 mentions for Mainz Biomed and 3 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 0.63 beat Mainz Biomed's score of -0.01 indicating that Tenax Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mainz Biomed 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tenax Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTenax Therapeutics beats Mainz Biomed on 9 of the 15 factors compared between the two stocks. Get Mainz Biomed News Delivered to You Automatically Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MYNZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYNZ vs. The Competition Export to ExcelMetricMainz BiomedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.01M$3.39B$6.04B$10.49BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-0.0222.9085.1927.32Price / Sales12.14269.18516.16194.55Price / CashN/A46.9537.5761.53Price / Book0.5710.5312.426.81Net Income-$21.65M-$52.58M$3.32B$276.59M7 Day Performance-7.50%1.06%0.80%0.15%1 Month Performance-6.03%16.05%10.52%8.17%1 Year Performance-87.11%18.41%76.14%35.50% Mainz Biomed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYNZMainz Biomed3.0209 of 5 stars$1.48-3.9%$14.00+845.9%-88.0%$8.01M$659.94K-0.0230Analyst ForecastTENXTenax Therapeutics2.6346 of 5 stars$7.41-0.7%$18.00+142.9%+98.2%$34.04MN/A-8.059Analyst ForecastMAAQMana Capital AcquisitionN/A$4.15-8.8%N/A-26.0%$33.72MN/A0.001Gap DownANVSAnnovis Bio2.8676 of 5 stars$1.64-3.8%$17.33+960.1%-77.6%$33.13MN/A-0.803Gap DownRANIRani Therapeutics3.3452 of 5 stars$0.47+2.2%$7.33+1,465.3%-84.8%$32.93M$1.03M-0.51110SCYXSCYNEXIS0.8351 of 5 stars$0.81+5.5%N/A-46.9%$32.28M$3.75M-2.0360News CoverageAnalyst ForecastGap UpTrading HaltedHigh Trading VolumeIMAImageneBio3.3634 of 5 stars$7.69-3.4%$35.50+361.6%-63.0%$31.88M$9.16M-1.0070Positive NewsXCURExicure1.9158 of 5 stars$5.14+3.8%N/A+97.7%$31.27M$500K-1.3250High Trading VolumeKZRKezar Life Sciences3.6976 of 5 stars$4.29+1.7%$9.00+109.8%-50.2%$30.90M$7M-0.4460AKTXAkari Therapeutics3.1516 of 5 stars$0.94+1.3%$3.30+250.4%-63.0%$30.33MN/A0.009News CoverageGap DownRNTXRein Therapeutics3.1322 of 5 stars$1.32+1.5%$10.00+657.6%N/A$30.30MN/A-0.499 Related Companies and Tools Related Companies Tenax Therapeutics Alternatives Mana Capital Acquisition Alternatives Annovis Bio Alternatives Rani Therapeutics Alternatives SCYNEXIS Alternatives ImageneBio Alternatives Exicure Alternatives Kezar Life Sciences Alternatives Akari Therapeutics Alternatives Rein Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYNZ) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
